8-K: Kewaunee Scientific Reports Strong Fiscal Year and Fourth Quarter Results Driven by Strategic Decisions

Kewaunee Scientific Corporation announced a 5% increase in fourth-quarter sales and significant improvements in full-year earnings, driven by strategic go-to-market decisions and non-recurring gains.

Summary

• Kewaunee Scientific Corporation reported a 5% increase in sales for the fourth quarter of fiscal year 2024, reaching $56.7 million, compared to $53.986 million in the same quarter of the previous year.
• The company's pre-tax earnings for the quarter were $1.347 million, down from $2.322 million in the prior year quarter, but adjusted pre-tax earnings, excluding non-recurring items, were $5.366 million, a 131% increase.
• Net earnings for the quarter were $11.026 million, significantly up from $1.005 million in the prior year quarter, primarily due to non-recurring tax benefits.
• Diluted earnings per share for the quarter were $3.71, compared to $0.34 in the prior year quarter, with adjusted diluted earnings per share at $1.55.
• EBITDA for the quarter was $2.265 million, down from $3.307 million in the prior year quarter, but adjusted EBITDA was $6.284 million.
• The company's order backlog increased to $155.6 million on April 30, 2024, up from $152.3 million on January 31, 2024, and $147.9 million on April 30, 2023.
• For the full fiscal year 2024, sales were $203.755 million, a decrease of 7.2% compared to $219.494 million in the prior year.
• Full-year pre-tax earnings were $13.119 million, up from $4.498 million in the prior year, with adjusted pre-tax earnings at $17.138 million, a 281% increase.
• Net earnings for the full year were $18.753 million, compared to $738,000 in the prior year, with adjusted net earnings at $12.319 million.
• Diluted earnings per share for the full year were $6.38, compared to $0.25 in the prior year, with adjusted diluted earnings per share at $4.19.
• EBITDA for the full year was $16.646 million, compared to $7.517 million in the prior year, with adjusted EBITDA at $20.665 million.
• The company's cash on hand increased to $25.938 million on April 30, 2024, from $13.815 million on April 30, 2023, primarily due to improved operating performance.
• The debt-to-equity ratio improved to 0.70-to-1 on April 30, 2024, from 1.08-to-1 on April 30, 2023.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with significant improvements in earnings and a strong order backlog, although there are some negative points such as a decrease in full year sales. The non-recurring items make it difficult to assess the underlying performance.

Positives

• The company experienced a 5% increase in sales for the fourth quarter.
• Adjusted pre-tax earnings for the fourth quarter increased by 131% year-over-year.
• Net earnings for the fourth quarter significantly increased due to non-recurring tax benefits.
• The company's order backlog increased to $155.6 million.
• Full-year adjusted pre-tax earnings increased by 281% year-over-year.
• Full-year net earnings showed a substantial increase compared to the previous year.
• The company's cash on hand increased significantly.
• The debt-to-equity ratio improved year-over-year.

Negatives

• Pre-tax earnings for the fourth quarter decreased compared to the prior year quarter before adjustments.
• EBITDA for the fourth quarter decreased compared to the prior year quarter before adjustments.
• Full-year sales decreased by 7.2% compared to the prior year.
• International sales for the full year decreased by 8.6% due to a large project not repeating.

Risks

• The company faces risks related to competitive and general economic conditions.
• There are risks associated with changes in customer demands and technological changes.
• The company is exposed to risks related to international operations, including foreign currency fluctuations.
• Changes in raw materials and commodity costs could impact profitability.
• The company faces risks associated with its ability to identify and complete strategic acquisitions.
• Acts of terrorism, war, governmental action, and natural disasters could impact operations.

Future Outlook

The company's order backlog of $155.6 million positions it well for fiscal year 2025, with continued solid levels of bidding and quoting.

Management Comments

• Fiscal year 2024 was a tremendous year for Kewaunee.
• The Company delivered strong financial results as we continue to realize the benefits of our strategic decisions made in recent years.
• These results have been recognized by the market, resulting in a significant increase in the Company's market capitalization during the year.
• We ended the fiscal year with an order backlog of $155.6 million, increasing from the prior year end.
• The strength of our order backlog indicates the stability of the markets we serve and our dealer and distribution partners' continued investment in serving our customers.
• We remain focused on Kewaunee's mission, which the Company has proudly pursued since its founding in 1906, which is to encourage new discovery worldwide.

Industry Context

The announcement reflects a positive trend in the laboratory and healthcare furniture industry, where strategic decisions and cost management can lead to improved profitability and market recognition.

Comparison to Industry Standards

• Kewaunee's adjusted EBITDA margin for the full year was approximately 10.1%, which is a significant improvement compared to the previous year, and is generally considered a good result in the manufacturing sector.
• Companies like Steelcase and Herman Miller, which operate in related sectors, often have EBITDA margins in the range of 8-12%, suggesting Kewaunee is performing competitively.
• The increase in Kewaunee's order backlog to $155.6 million indicates strong future demand, which is a positive sign compared to industry peers who may be experiencing flat or declining backlogs.
• The company's debt-to-equity ratio of 0.70-to-1 is also a positive sign, indicating a healthy balance sheet compared to some competitors who may have higher leverage.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and increased market capitalization.
• Employees will benefit from the company's success and continued growth.
• Customers will benefit from the company's commitment to delivering high-quality products and services.
• Suppliers will benefit from the company's continued operations and growth.
• Creditors will benefit from the company's improved financial health and reduced debt-to-equity ratio.

Next Steps

• The company will continue to focus on its mission to encourage new discovery worldwide.
• The company will continue to execute its strategic decisions to improve profitability.
• The company will continue to monitor bidding and quoting levels for future projects.

Key Dates

Keywords

financial results, earnings, sales, EBITDA, backlog, debt-to-equity, laboratory furniture, healthcare furniture, Kewaunee Scientific, non-recurring transactions